feed,title,long_url,short_url
Benzinga,Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA,https://benzinga.com/general/biotech/22/01/25128307/omeros-submits-response-to-fda-regarding-narsoplimab-application-in-hsct-tma,https://bit.ly/3GO3S06
Benzinga,"Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022",https://benzinga.com/general/biotech/22/01/25128078/liminal-biosciences-pauses-development-of-fezagepras-outlines-r-d-priorities-for-2022,https://bit.ly/3qIG5Js
